Clinical Trial

A Phase III Clinical Study of Adebrelimab Combined With Concurrent Chemoradiotherapy Versus Placebo Combined With Concurrent Chemoradiotherapy for the Treatment of Locally Advanced Cervical Cancer

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This study aims to evaluate the efficacy of Adebrelimab plus concurrent chemoradiotherapy compared with placebo plus concurrent chemoradiotherapy for the treatment of locally advanced cervical cancer by evaluating progression-free survival (PFS).
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-09-04; most recent amendment 2026-04-12.
Status change: Not Yet Recruiting → Recruiting 2025-11-13
Trial Details
NCT Number NCT07168200
Lead Sponsor Shanghai Shengdi Pharmaceutical Co., Ltd
Conditions Advanced Cervical Cancer
Enrollment 720 participants
Start Date 2025-10-17
Primary Completion 2028-04 (estimated)
Study Completion 2028-12 (estimated)
Updated on ClinicalTrials.gov 2026-04-15